Related Experiment Video

Updated: May 16, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Multiple sclerosis: new measures to monitor the disease

Massimo Filippi1, Maria A Rocca

  • 1Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, 20132 Milan, Italy. filippi.massimo@hsr.it

The Lancet. Neurology
|December 15, 2012
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Related Experiment Videos

Last Updated: May 16, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Articles linked to this work by shared authors, journal, and citation graph.

Harmonized Acquisition of Connectome MRI and Clinical Data for Stroke, Parkinson's Disease and Glioma: Delphi-Derived Protocol Recommendations by the European Academy of Neurology.

European journal of neurology·2026

Prevalence of Slowly Expanding Lesions in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis.

Neurology·2026

Pediatric multiple sclerosis: a diagnostic overview and the importance of early identification.

Expert review of neurotherapeutics·2026

Subjective sleep disturbances are associated with reduced MRI-derived perivascular-space diffusivity in multiple sclerosis.

Journal of neurology·2026

Investigating the association between grey matter hypoperfusion and atrophy in multiple sclerosis using arterial spin labelling.

Brain communications·2026

Vascular risk factors' impact on motor performance and sensorimotor network structural integrity in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Plasma phosphorylated tau 217 concentrations, APOE genotype, and timing of cognitive impairment in individuals across diverse racial and ethnic groups: a pooled analysis of prospective cohort studies.

The Lancet. Neurology·2026

Clinical pathways for cognitively unimpaired individuals with Alzheimer's disease neuropathological change.

The Lancet. Neurology·2026

Neuroimaging in the era of biologically defined Alzheimer's disease and disease-modifying therapy.

The Lancet. Neurology·2026

Fluid biomarkers in the evolving care landscape of Alzheimer's disease and related disorders.

The Lancet. Neurology·2026

Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

The Lancet. Neurology·2026

Prevalence of unruptured intracranial aneurysms according to comorbidities, risk factors, country, and time period: a systematic review and meta-analysis.

The Lancet. Neurology·2026

Leveraging a Deep Learning Model and Computational Screening for the Discovery of ABCG2 Inhibitors against Drug-Resistant Breast Cancer.

Journal of chemical information and modeling·2026

Calcium phosphate nanoparticles carrying YAP plasmid promote osteogenic potential in dental pulp stem cells by modulating BMP-2 expression and macrophage M2-like phenotype.

Connective tissue research·2026

A trial emulation study indirectly comparing tafamidis and acoramidis in transthyretin amyloid cardiomyopathy: the ReplicATTR study.

Journal of comparative effectiveness research·2026

Research Progress of Traumatic Brain Injury and Its Related Markers.

Clinical laboratory·2026

Discovery of human antibody specific to the spike glycoprotein subunit 2 of SARS-CoV-2 and characterization of its broad-spectrum neutralizing activity.

Infectious medicine·2026

Single-cell vector copy number analysis of phenotypically defined long-term hematopoietic stem cells for gene therapy safety assessment.

Molecular therapy. Advances·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us